Nom du chef d’Unité : Pr Dominique SALMON-CERON
Nom du chef de Pôle Pr Loic GUILLEVIN Mail dominique.salmon@cch.aphp.fr
Thématique 1 : Coinfection VIH hépatites
Mots clés : VIH, hépatite C
Responsable scientifique : D Salmon-Ceron Mail : dominique.salmon@cch.aphp.fr
Intitulé de l’équipe : HEPAVIH Cohorte ANRS 013
Encadrement de master ou thèse oui
Thématique 2 : Risque infectieux et biothérapies
Mots clés : infections opportunistes, immunodépression, immunomodulateurs
Responsable scientifique : D Salmon-Ceron Mail : dominique.salmon@cch.aphp.fr
Intitulé de l’équipe : Réseau Inserm en santé des populations RATIO «
Encadrement de master ou thèse non
Thématique 3 : Infections ostéo articulaires
Mots clés : infections sur prothése, maladies inflamamtoires, rhumatolgie,
Responsable scientifique : valérie Dumaine Mail : valerie.dumaine@cch.aphp.fr
Intitulé de l’équipe :
Encadrement de master ou thèse non
1. TUBACH F., RAVAUD P., SALMON-CERON D., PETITPAIN N., BROCQ O., GRADOS F.,GUILLAUME JC., LEPORT J., ROUDAUT A., SOLAU-GERVAIS E., MARIETTE X. and LORTHOLARY O for the RATIO Group. Emergence of Legionella pneumophila pneumonia in patients receiving TNF-a antagonists: 10 cases from a French registry. Clin Infect Dis. 2006 ;43 :95-100. 2006.16.
2. TUBACH F., SALMON-CERON D., RAVAUD P., MARIETTE X. pour le groupe RATIO. RATIO: a rench registry of opportunistic infections, severe bacterial infections and lymphomas in patients treated with TNF blockers. Joint Bone Spine 2005;72:456-60.
3. SALMON-CERON D., ROSENTHAL E., LEWDEN C., BOUTELOUP V., MAY T., BURTY C., BONNET F., COSTAGLIOLA D., JOUGLA E., SEMAILLE C., MORLAT P., CACOUB P., CHENE G., Emerging role of hepatocellular carcinoma among liver related causes of deaths in HIV infected patients : The French National Mortalité 2005 study. J Hepatol. 2009;50(4):736-45.
4. TRICOT L., TEICHER E., PEYTAVIN G., ZUCMAN D., CONTI F., CALMUS Y., VALANTIN M.A., DUVIVIER C., FONTAINE C., WELKER Y., BILLY C., VITTECOQ D., SALMON-CERON D., Safety and efficacy of raltégravir containing regimen in HIV infected transplanted patients cotreated with immonusuppressive drugs. Am J Transplant. 2009;9(8):1946-52.
5. BONNET F., BURTY C., LEWDEN C., COSTAGLIOLA D., MAY T., ROSENTHAL E., JOUGLA E., CACOUB P., SALMON-CERON D., CHENE G., MORLAT P., the ANRS EN 19 Mortality Study Group and Mortavic. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis. 2009;48(5):633-9.
6. ROSENTHAL E., SALMON-CERON D., LEWDEN C;, BONNET F., MAY T., MORLAT P., FRANCOIS M., BURTY C;, JOUGLA E., COSTAGLIOLA D., CHENE G., CACOUB P., Liver-related deaths in human immunodeficiency virus-infected patients between 1995 and 2005 in the French GERMIVIC joint study Group (Mortavic 2005 Study in collaboration with MORTALITE 2005 surveys, ANRS EN 19), HIV Med. 2009;10(5):282-9.
7. WIRTZ V., ODESHOO L., VAN DEN DUNGEN M., GRUBER C., LEDESMA E. AND SWAN STUDY GROUP. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007 Jun 1;44(11) :1484-92
8. GIUGLIANI C., VIDAL-TRECAN G., TRAORE S., BLANCHARD H., SPIRIDON G., ROLLOT F., LAUNAY O., GOROVESTSKI M., MARANDE J-L., VINSONNEAU C., GUILLEVIN L., SALMON-CERON D. Feasibility of azithromycin prophylaxis during a pertussis outbreak among healthcare workers in a university hospital in Paris; ICHE. 2006 Jun;27 (6) :626-9.
9. GAHERY H., DANIEL N., CHARMETEAU B., OURTH L., JACKSON A., ANDRIEU M., CHOPPIN J., SALMON-CERON D., PIALOUX G., GUILLET JG.. New CD4+ and CD8+ cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type-1 lipopeptide vaccine. AIDS RHR. 2006; 22(7):684-94.
Nom du chef de service Dr Odile Launay (chef d’UF), Pr Loïc Guillevin (responsable de pôle) Mail : odile.launay@cch.aphp.fr
Thématique 1 : vaccinologie
Mots clés : essais cliniques ; immunodéprimés ; vaccination
Responsable scientifique : Dr O Launay Mail odile.launay@cch.aphp.fr
Intitulé de l’équipe : Centre d’investigation Clinique de vaccinologie Cochin Pasteur
Encadrement de master ou thèse oui
Thématique 2 : infection par le VIH
Mots clés : pharmacologie clinique ; transmission mere-enfant
Responsable scientifique : Pr Christine Rouzioux Mail christine.rouzioux@nck.aphp.fr
Intitulé de l’équipe : Infection à VIH : réservoirs et résistance aux traitements
Encadrement de master ou thèse oui
1. Silbermann B, Tod M, Desaint C, Heshmati F, Pialoux G, Petitprez K, Slama L, Poncelet H, Moreau C, Mazarin V, Heshmati F, Salmon Céron D, Guillet JG, Launay O. Long term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retrov, in press
2. Launay O, Grabar S, Gordien E, Desaint C, Dimet J, Jegou D, Girard PM, Williams V, Salmon D, Abad S, Lortholary O, Rey D, and HEPAVAC Study Group Immunological. Efficacy of a Three-Dose Schedule of Hepatitis A Vaccine in HIV-infected Adults: HEPAVAC Study. J Acquir Immune Defic Syndr 2008, in press
3. Charlier C, Henegar C, Launay O, Berezne A, Bienvenu B, Pagnoux C, Cohen P, Mouthon L, Guillevin L. Risk factors for severe infections in Wegener Granulomatosis: analysis of 113 patients. Ann Rheum Dis 2008, May 26. [Epub ahead of print].
4. Launay O, Grabar S, Bloch F, Desaint C, Jegou D, Lallemand C, Erickson R, Lebon P, Tovey MG. Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008;26(32): 4073-9.
5. Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales-Canali G, Cuzin L, Figueiredo S, Surenaud M, Hamouda NB, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault-Villada I, Guillet JG, for the ANRS-VAC16 trial group. Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial. PLos ONE 2007; 2(8):e725.
6. Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F; ANRS 109 VISTA Study Group. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109). Antiviral Therapy. 2006 ;11:889-899.
7. Bresson JL, C Perronne C, Launay O, Gerdil C, Saville M, Kazek MP, Wood J, Höschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial Lancet. 2006;367:1657-64.
8. Durier C*, Launay O*, Meiffrédy V, Saïdi, Salmon D, Lévy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. Aids. 2006 ;20:1039-1049. *The first two authors contributed equally to this work.
9. Launay O, Roudiere L, Boukli N, Dupont B, Prevoteau du Clary F, Patey O, David F, Lortholary O, Devidas A, Piketty C, Rey E, Urbinelli R, Allaert FA, Treluyer JM, Caumes E. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: Results of the viramune-zyrtec double-blind, placebo-controlled trial. Clin Infect Dis. 2004;38:e66-72.
10. Launay O, Tod M, Louchahi K, Belarbi L, Bouchaud O, Memain N, Petitjean O, Robineau M, Guillevin L, Lortholary O. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother. 2004;48:632-634.
